AMRS News and Press, Amyris Inc. From 12/19/22

Hot Penny Stocks To Buy For Under $3 Are you looking for penny stocks to buy today? You’re not alone, and the process of finding them isn’t as easy as you might think. One of the main reasons is the much higher volatility in the stock market today. It isn’t just penny s...

Summary Amyris is on the cusp of closing a record strategic transaction slated to generate ~$500mm in cash value. All indications point to a transaction closing in the next two to three weeks. Cash balances by year-end projected to be >$350mm after the strategic transaction close...

AMYRIS CONSUMER BRANDS DELIVER 80% CYBER MONDAY LIKE-FOR-LIKE GROWTH PR Newswire EMERYVILLE, Calif. , Nov. 30, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable consumpti...

AMYRIS CONSUMER BRANDS DELIVER RECORD BLACK FRIDAY WEEK SALES PR Newswire EMERYVILLE, Calif. , Nov. 28, 2022 /PRNewswire/ -- Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the world's transition to sustainable con...

Are You Looking For The Best Penny Stocks To Buy Now? Unusual Options Activity Could Give Some Clues If you’re hunting for the best penny stocks to buy, your choices are pretty open. Thanks to the stock market crash this year, plenty of popular companies have slumped to some of t...

Synthetic-biology company Amyris (NASDAQ: AMRS) had an absolutely awful day on the stock exchange Wednesday, due to an earnings report that fell well short of expectations. Investors mercilessly punished the company, driving its share price down a vertigo-inducing 41%. After mar...

Summary Investor expectations for the third quarter were not realistic given deterioration in the macro environment and Amyris’ cost structure. There was no improvement in gross margins due to high freight costs, continued production in Spain and potentially due to insourci...

Summary Amyris, Inc. reported another set of disappointing quarterly results in Q3, with both revenue and earnings missing consensus expectations by a mile. Amyris cash usage remained at elevated levels. In addition, gross margins continued to be hurt by higher freight and lo...

Amyris, Inc. ( NASDAQ: AMRS ) lost ~33% pre-market Wednesday after announcing lower-than-expected financials for Q3 2022, which prompted Oppenheimer to downgrade the synthetic biotech company to Perform from Outperform. Oppenheimer noted that the company fell short of it...

Amyris, Inc. (AMRS) Q3 2022 Earnings Conference Call November 08, 2022 04:30 PM ET Company Participants Han Kieftenbeld - Chief Financial Officer John Melo - President & Chief Executive Officer Eduardo Alvarez - Chief Operating Officer Conference Call P...